Valuation: Jazz Pharmaceuticals plc

Market Cap 15.45B 14.03B 12.96B 11.69B 22.07B 1,444B 22.91B 156B 61.75B 779B 57.97B 56.75B 2,461B P/E 2026 *
62.4x
P/E 2027 * 14.5x
Enterprise Value 18.3B 16.61B 15.34B 13.84B 26.13B 1,709B 27.13B 185B 73.13B 922B 68.65B 67.2B 2,915B EV / Sales 2026 *
3.8x
EV / Sales 2027 * 3.26x
Free-Float
96.33%
Yield 2026 *
-
Yield 2027 * -
1 day+0.92%
1 week-2.16%
Current month+12.45%
1 month+16.52%
3 months-4.03%
6 months+5.80%
Current year+42.86%
1 week 235.89
Extreme 235.89
249.99
1 month 202.3
Extreme 202.3
249.99
Current year 156.95
Extreme 156.95
266.38
1 year 156.95
Extreme 156.95
266.38
3 years 95.49
Extreme 95.49
266.38
5 years 95.49
Extreme 95.49
266.38
10 years 86.88
Extreme 86.88
266.38
Manager TitleAgeSince
Chief Executive Officer 54 11/08/2025
Director of Finance/CFO 62 01/03/2024
Chief Tech/Sci/R&D Officer 54 01/08/2023
Director TitleAgeSince
Chairman 62 01/03/2003
Director/Board Member 65 18/01/2012
Director/Board Member 66 01/01/2010
Date Insider Type Main position Quantity % Market Cap. Importance
03/11/26 Sell

Chief Executive Officer

-1,000 0.0015%
02/11/26 Sell

Founder

-6,000 0.0092%
06/10/26 Sell

Chief Executive Officer

-2,000 0.0031%
Change 5-day change 1-year change 3-year change Capi.($)
+0.92%-2.16%+34.54%+101.30% 15.45B
-1.94%-3.24%+35.02%+132.72% 1,261B
-1.32%-1.95%+37.47%+83.40% 671B
-1.58%-2.26%+23.27%+108.44% 518B
-0.80%+0.62%+31.86%+70.52% 387B
-2.65%-5.17%+44.74%+35.93% 353B
-1.32%-0.60%+29.35%+56.55% 300B
-1.60%-2.09%+0.29%+34.63% 283B
-2.43%-4.42%+30.07%+68.62% 248B
-1.06%-0.64%+32.60%+121.89% 211B
Average -1.34%-0.48%+29.92%+81.40% 425B
Weighted average by Cap. -1.65%-0.55%+31.37%+91.94%

Financials

2026 *2027 *
Net sales 4.81B 4.37B 4.03B 3.64B 6.87B 449B 7.13B 48.59B 19.22B 242B 18.04B 17.66B 766B 5.07B 4.6B 4.25B 3.83B 7.23B 473B 7.51B 51.19B 20.25B 255B 19.01B 18.61B 807B
Net income 267M 242M 224M 202M 381M 24.95B 396M 2.7B 1.07B 13.46B 1B 981M 42.54B 1.14B 1.03B 954M 861M 1.63B 106B 1.69B 11.5B 4.55B 57.38B 4.27B 4.18B 181B
Net Debt 2.85B 2.58B 2.39B 2.15B 4.06B 266B 4.22B 28.76B 11.37B 143B 10.68B 10.45B 453B 1.05B 957M 884M 797M 1.51B 98.45B 1.56B 10.65B 4.21B 53.13B 3.95B 3.87B 168B
Projected Income Statement - Annual - Jazz Pharmaceuticals plc
Logo Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, ABS-1230, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Employees
2,890
Date Price Change Volume
18/11/26 $242.87 +0.90% 75,749
17/11/26 $240.71 +0.39% 499,524
16/11/26 $239.77 -0.74% 490,232
13/11/26 $241.55 +0.49% 496,703
12/11/26 $240.37 -3.17% 584,415
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Jazz Pharmaceuticals plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
240.71USD
Average target price
297.50USD
Spread / Average Target
+23.59%
  1. Stock Market
  2. Stocks
  3. JAZZ Stock